Review Article
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
Table 2
Translational studies with immunotherapeutics targeting myeloma cells. Dara: daratumumab, len: lenalidomide, dex: dexamethasone, bort: bortezomib.
| | Target | Pre-clinical evidence | Phase 1/2 trials | Phase 3 trials |
| | B2M | Anti-B2M Ab (xenograft) [190] | Not progressed to human trials | |
| | BCMA | CD3-BCMA BiTE (xenograft) [125] | NCT02514239 | | | CAR-T (xenograft) [78, 79] | 11D5-3-CD828Z[80] | | | bb2121(contains 4-1BB) [81] | NCT02658929 | |
| | CD38 | Daratumumab causes MM cell apoptosis in xenograft models [191] | Phase 1: GEN501[96] | Dara/len/dex[98] | | Phase 1/2: SIRIUS[97] | Dara/bort/dex[99] | | α-radioimmunotherapy (5T33)[108] | Not progressed to human trials | |
| | CD138 | α-radioimmunotherapy (5T33)[104–107] | Phase 1 dosimetry study[110] | | | CAR-NK cells (NOD-SCID xenograft)[82] | Not progressed to human trials | |
| | CS1 | CAR-NK cells (NSG xenograft)[83] | Not progressed to human trials | |
| | FcRH5 | CD3-FcRH5 BiTE (xenograft)[192] | NCT03275103 | |
| | VLA-4 | (5TGM1)[193] | Not progressed to human trials | |
|
|
